Cancer Clinical Trial
Official title:
Activating Happiness in Cancer: A Positive Psychology Workshop for Patients, Survivors, and Caregivers
NCT number | NCT03569657 |
Other study ID # | 1203830-2 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | June 6, 2018 |
Est. completion date | January 28, 2019 |
Verified date | December 2023 |
Source | University of Denver |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The number of worldwide cancer survivors is projected to be 21.3 million by 2030. To treat this growing population, group psychological interventions are increasingly utilized and require empirical support to evaluate their effectiveness. To address the need to assess positive group psychological interventions for cancer survivors and caregivers that incorporates diverse conceptualizations of adaption and examines both mental and physical health outcomes, this project is a study on a 4-week psychoeducation intervention group entitled "Activating happiness in cancer: A positive psychology workshop for patients, survivors, and caregivers." The project will evaluate the following hypotheses: (1) Participation in a positive psychology workshop will predict higher levels of well-being, mindfulness, gratitude, and vitality for cancer survivors and caregivers at the end of the group, and these changes will be maintained 3 months after the group has ended; and (2) Participation in a positive psychology intervention group will predict lower levels of depression, anxiety, pain, fatigue, loneliness, and healthcare utilization for cancer survivors and caregivers at the end of the group, and these changes will be maintained 3 months after the group has ended. Additionally, the project poses the following question: (1) What elements of positive psychological workshop do cancer survivors and caregivers perceive as most meaningful?
Status | Completed |
Enrollment | 49 |
Est. completion date | January 28, 2019 |
Est. primary completion date | January 28, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Above the age of 18 - either has received a cancer diagnosis OR - is the caregiver of someone with a cancer diagnosis Exclusion Criteria: - Under the age 18 - Does not speak English - Has not received a cancer diagnosis nor is the caregiver of someone with a cancer diagnosis |
Country | Name | City | State |
---|---|---|---|
United States | Rocky Mountain Cancer Centers | Denver | Colorado |
Lead Sponsor | Collaborator |
---|---|
University of Denver | Rocky Mountain Cancer Centers |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in Fatigue | Multidimensional Fatigue Syndrome Inventory-Short Form (Stein, Jacobsen, Blanchard, & Thors, 2004). Score by summing individual subscales (General and Vigo subscales), ranging from 0 to 48. Higher scores indicate greater levels of fatigue. General scale = sum of items 10, 12, 14, 17, 18, and 28 Vigor scale = sum of items 5, 7, 9, 22, 24, and 29 |
Change from baseline to after 2nd session (2 weeks), baseline to after final session (4 weeks), baseline to after 3 months after final session (up to 16 weeks) | |
Other | Change in Loneliness | Three-Item Loneliness Scale (Hughes, Waite, Hawkley, & Cacioppo, 2008). Scores are summed to totaling all of the items, with a possible range from 0-9. Higher scores indicate higher levels of loneliness. | Change from baseline to after 2nd session (2 weeks), baseline to after final session (4 weeks), baseline to after 3 months after final session (up to 16 weeks) | |
Other | Change in Healthcare utilization | Self-created questions asking how many times in the past week have you sought medical care that was not prescheduled. Items are not scored, and information is only being collected for background data. | Change from baseline to after 2nd session (2 weeks), baseline to after final session (4 weeks), baseline to after 3 months after final session (up to 16 weeks) | |
Other | Changes in Gratitude | Gratitude Questionnaire-Six Item Form (McCullough, Emmons, & Tsang, 2002). To score, add up your scores for items 1, 2, 4, and 5. Add the reversed scores for items 3 and 6 to the total from Step 1. This is your total GQ-6 score. This number should be between 6 and 42. Higher scores indicate higher levels of gratitude. | Change from baseline to after 2nd session (2 weeks), baseline to after final session (4 weeks), baseline to after 3 months after final session (up to 16 weeks) | |
Other | Change in Mindfulness | State Mindfulness Scale (Tanay & Bernstein, 2013). Scores are totaled by summing all items, ranging from 21-105. Higher scores indicate higher levels of state mindfulness. | Change from baseline to after 2nd session (2 weeks), baseline to after final session (4 weeks), baseline to after 3 months after final session (up to 16 weeks) | |
Other | Change in Self-Compassion | Self-Compassion Scale-Short Form (Neff, 2003). A total self-compassion score is computed by reversing the negative subscale items and then adding all subscale scores. Scores can range from 12-60, with higher scores indicating greater levels of self-compassion. | Change from baseline to after 2nd session (2 weeks), baseline to after final session (4 weeks), baseline to after 3 months after final session (up to 16 weeks) | |
Other | Change in Pain | Brief Pain Inventory (Daut, Cleeland, & Flanery, 1983). Scores are summed to totaling all of the items, with a possible range from 0-50. Higher scores indicate more pain. | Change from baseline to after 2nd session (2 weeks), baseline to after final session (4 weeks), baseline to after 3 months after final session (up to 16 weeks) | |
Other | Change in Meaning in Life | Meaning in Life Questionnaire (Steger, Frazier, Oishi, & Kaler, 2006). Two subscales are totaled, one for the presence of life meaning (ranging from 0-35, higher levels indicate higher levels of life meaning) and one for the search for life meaning (ranging from 0-35, with higher levels indicating greater efforts directed at searching for life meaning). | Change from baseline to after 2nd session (2 weeks), baseline to after final session (4 weeks), baseline to after 3 months after final session (up to 16 weeks) | |
Primary | Change in Depression | Personal Health Questionnaire Depression Scale (Kroenke et al., 2009). "A total PHQ-8 score of 10 or greater in the clinical setting should prompt a careful interview for a number of reasons: to determine if the elevated score represents clinical depression, to consider confounding medical causes, to evaluate for affective disorders that may warrant either more conservative initial treatment than major depression (e.g., minor depression or bereavement) or earlier mental health referral (e.g., bipolar disorder or comorbid substance abuse), and to avoid premature labeling of a person as having depression." | Change from baseline to after 2nd session (2 weeks), baseline to after final session (4 weeks), baseline to after 3 months after final session (up to 16 weeks) | |
Secondary | Change in Anxiety | Generalized Anxiety and Depression (Spitzer, Kroenke, Williams, & Lowe, 2006). Scores are summed to get the total score, which can range from 0-21. Anxiety Severity Level: Minimal: 0-4 Mild: 5-9 Moderate: 10-14 Severe: 15-21 |
Change from baseline to after 2nd session (2 weeks), baseline to after final session (4 weeks), baseline to after 3 months after final session (up to 16 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|
||
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|